Combined Research Orlando Phase I-Iv — Orlando, Florida

Combined Research Orlando Phase I-Iv is a clinical research site located in Orlando, Florida, United States 32807.

Crixeo Clinical Trials Trust Score: 23/100 (FAILING). This profile has not yet been claimed by the site owner.

Combined Research Orlando Phase I-Iv has participated in 28 clinical trials with 12 currently active.

Therapeutic areas: Major Depressive Disorder, Depressive Disorder, Major, Immunoglobulin A Nephropathy.

Sponsors: Xenon Pharmaceuticals Inc., Naurex, Inc, an affiliate of Allergan plc, Alpine Immune Sciences Inc, A Subsidiary of Vertex.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Orlando

Browse all research sites in Florida · View every site in Orlando

Sponsor Feasibility Report

Trust Score: 23/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Combined Research Orlando Phase I-Iv?

Combined Research Orlando Phase I-Iv has a Crixeo Trust Score of 23/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Combined Research Orlando Phase I-Iv conducted?

Combined Research Orlando Phase I-Iv has 28 clinical trials on record, with 12 currently active. Their work covers Major Depressive Disorder, Depressive Disorder, Major, Immunoglobulin A Nephropathy.

Is Combined Research Orlando Phase I-Iv accredited by Crixeo Clinical Trials?

Combined Research Orlando Phase I-Iv has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Combined Research Orlando Phase I-Iv?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.